Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success
Résumé
Comment on
CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. [EMBO Mol Med. 2016]
Domaines
Médecine humaine et pathologie
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...